

---

# S&P TEST

SWOT & PESTLE.com

---

## MODERNA SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. To purchase reprints of this document, please email [support@swotandpestle.com](mailto:support@swotandpestle.com).

**Company Name :** Moderna

**Company Sector :** Biotechnology

**Operating Geography :** USA, North America

**About the Company :** Moderna Inc. functions as a messenger RNA therapeutics biotechnology company. The firm is developing and researching drugs to generate proteins or antibodies inside human cells. Instead of being produced externally and inserted as in traditional drugs, the Moderna Technology Platform is to implant synthetic mRNA into living cells that will reprogram the cells to establish immune responses. It is an innovative approach abandoned by many major pharmaceutical and biotechnology firms who have been unable to resolve the side effects of RNA injection into cells. Different medication modes such as prophylactic vaccinations, preventive vaccines, intra - tumoral immuno-oncology, targeted therapeutics and intracellular liver are included in the pipeline. Moderna also offers therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology and cardiovascular disease. It is headquartered in Cambridge, Massachusetts, the US. In December 2018, Moderna became the highest initial public biotech offering (IPO) in history, raising US\$ 600 million for 8% of its shares, indicating overall valuation of \$7.5 billion.

Moderna's mission is to "Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients."

**Revenue :**

US \$803 million – FY ended Dec 31st 2020

US\$ 60.2 million – FY ended Dec 31st 2019

US\$ 135.1 million – FY ended Dec 31st 2018 ?

**SWOT Analysis :**

The SWOT Analysis for Moderna is given below:

Strengths	Weaknesses
<ul style="list-style-type: none"> <li>1.Strong proprietary infrastructure</li> <li>2.Strategic alliances to accelerate advancement of potential mRNA drugs</li> <li>3.Patent and IP estate as strategic assets</li> <li>4. COVID-19 vaccine from Moderna's stable helping fight global health emergency</li> </ul>	<ul style="list-style-type: none"> <li>1.Poor track record with no marketable product and no revenue</li> <li>2.Continuous losses since inception</li> <li>3.Lack of experience in sales and distribution</li> </ul>
Opportunities	Threats
<ul style="list-style-type: none"> <li>1.Massachusetts as a booming biotech hub</li> <li>2.mRNA potential for new class of medicines</li> <li>3.Untapped local production</li> </ul>	<ul style="list-style-type: none"> <li>1.COVID-19 vaccine efficiency and resultant side effects may attract fresh trouble for the pharma giant</li> <li>2.Dependence on progression of modalities</li> <li>3.Regulatory changes may increase the competition from biosimilars</li> <li>4.Risks inherent in pharmaceutical operations and supply chain</li> </ul>

## PESTLE Analysis :

The PESTLE Analysis for Moderna is given below:

<p style="text-align: center;"><b>Political</b></p> <p>1.Impact of US elections on pharma industry amidst COVID-19 vaccine developments 2.Pricing pressures from US government</p>	<p style="text-align: center;"><b>Economical</b></p> <p>1.Induced demand due to panic buying even with low disposable incomes</p>
<p style="text-align: center;"><b>Social</b></p> <p>1.Ageing population in developed countries 2.Shift in communication to remote interactions by tele-communication and tele-health</p>	<p style="text-align: center;"><b>Technological</b></p> <p>1.Emerging new technologies like gene therapy and reverse paralysis 2.Rise of connected patient through mobile technology and social media 3.Blockchain to benefit drugs supply chain</p>
<p style="text-align: center;"><b>Legal</b></p> <p>1.Uphill legal journey for drug development exhausts a lot of time and financial resources</p>	<p style="text-align: center;"><b>Environmental</b></p> <p>1.Development of drug resistance in drug production areas leading to severe environmental impact</p>

Please note that our free summary reports contain the SWOT and PESTLE table contents only.

The complete report for **Moderna** SWOT & PESTLE Analysis is a paid report at **12.53 U.S.D.**



\* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



# S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

# Copyright Notice

The information provided in the SWOT and PESTLE research reports on [www.swotandpestle.com](http://www.swotandpestle.com) are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2023 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:  
[support@swotandpestle.com](mailto:support@swotandpestle.com)